Litigation Details for Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd. (D. Del. 2019)

Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd. (D. Del. 2019)

Docket		Date Filed	2019-07-17
Court	District Court, D. Delaware	Date Terminated	2019-12-03
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	LUYE PHARMA (USA) LTD.
Patents	6,667,061
Attorneys	Scott A. Cunning , II
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-07-17				External link to document
2019-07-17	1	Complaint	infringement of United States Patent No. 6,667,061 (“the ’061 patent”) under the Patent Laws of the United States…infringed one or more claims of United States Patent No. 6,667,061 by submitting NDA No. 212849 seeking FDA… before the expiration of United States Patent No. 6,667,061 including any extensions and additional…infringe one or more claims of United States Patent No. 6,667,061 under 35 U.S.C. §§ 271(a), (b), and/or (…day after the expiration of United States Patent No. 6,667,061, inclusive of any extensions or additional	External link to document
2019-07-17	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,667,061 B2. (sam) (Entered:…2019 3 December 2019 1:19-cv-01340 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-07-17	58	Stipulation of Dismissal	Defendants”) for infringement of U.S. Patent No. 6,667,061 (the “Patent” and such action, the “Litigation”…DISMISSAL WHEREAS, this action for patent infringement has been brought by Plaintiffs Alkermes…2019 3 December 2019 1:19-cv-01340 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Alkermes v. Luye Pharma Group Ltd. Litigation Summary, Case No. 1:19-cv-01340

Last updated: August 3, 2026

Alkermes Pharma Ireland Limited sued Luye Pharma Group Ltd. in the U.S. District Court for the District of Delaware after Luye filed an abbreviated new drug application seeking approval to market a generic version of Aristada, Alkermes’ extended-release aripiprazole lauroxil injection. The case was a Hatch-Waxman patent action involving Alkermes’ long-acting injectable formulation and related patent claims.

The litigation ended by dismissal following settlement rather than a reported trial judgment. The settlement terms were not publicly disclosed. The case therefore produced no public ruling establishing the asserted patents’ validity, enforceability, or infringement against Luye.

What drug and product were at issue in Alkermes v. Luye?

The dispute concerned Aristada, an extended-release injectable suspension containing aripiprazole lauroxil.

Item	Detail
Brand	Aristada
Active ingredient	Aripiprazole lauroxil
Dosage form	Extended-release injectable suspension
Administration	Intramuscular injection
Sponsor	Alkermes, Inc. and affiliates
FDA approval	2015
Regulatory application	Luye ANDA for a generic aripiprazole lauroxil injectable product
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:19-cv-01340
Case type	Hatch-Waxman patent litigation
Outcome	Dismissed following settlement

Aristada is a prodrug formulation of aripiprazole designed to release aripiprazole over an extended period after intramuscular administration. The product competes in the long-acting injectable antipsychotic market with Abilify Maintena, which contains aripiprazole monohydrate and is marketed by Otsuka and its commercial partners.

When was the lawsuit filed and why did Alkermes sue Luye?

Alkermes filed the action in 2019 after receiving notice that Luye had filed an ANDA containing a Paragraph IV certification against Aristada-related patents. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The filing of the lawsuit triggered the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions. During the stay, the FDA generally could not grant final approval to Luye’s ANDA.

The complaint alleged that Luye’s proposed product would infringe one or more Alkermes patents covering aripiprazole lauroxil compositions, injectable formulations, and related use or manufacturing technology. The litigation was filed as:

Field	Information
Plaintiff	Alkermes Pharma Ireland Limited
Defendant	Luye Pharma Group Ltd.
Court	District of Delaware
Case number	1:19-cv-01340
Presiding judge	Judge Richard G. Andrews
Legal basis	Patent infringement under 35 U.S.C. § 271(e)(2)
Trigger	Luye ANDA and Paragraph IV certifications
Product	Generic aripiprazole lauroxil extended-release injection

What patents protected Aristada in the Luye litigation?

The complaint involved Alkermes patent rights associated with aripiprazole lauroxil and Aristada’s long-acting injectable delivery system. Public Aristada patent records identify several relevant patent families, including the following:

Patent	General subject matter	Relevance
U.S. Patent No. 8,337,888	Aripiprazole lauroxil compositions and related pharmaceutical technology	Foundational product and formulation protection
U.S. Patent No. 9,193,987	Long-acting aripiprazole lauroxil formulations and delivery	Product and formulation protection
U.S. Patent No. 9,925,241	Injectable aripiprazole lauroxil formulations and related technology	Later-issued formulation protection
Additional continuation patents	Related composition, dosage, administration, and manufacturing claims	Potentially relevant to later generic entry

Patent scope must be assessed claim by claim. A patent’s listing in the FDA Orange Book does not establish that every generic product infringes it. It also does not establish validity or enforceability.

The asserted claims were commercially important because aripiprazole lauroxil is not protected only by the active pharmaceutical ingredient. Alkermes’ estate has been directed toward the prodrug itself, particle and formulation properties, extended-release behavior, injectable suspension technology, and dosing or administration methods.

What formulation patents protect Aristada?

The formulation patent estate is directed to technology that can control release of aripiprazole after intramuscular administration. Relevant claim categories may include:

• Aripiprazole lauroxil particles or compositions.
• Injectable suspensions containing the prodrug.
• Particle-size distributions and release characteristics.
• Excipients and suspension vehicles.
• Extended-release pharmacokinetic profiles.
• Dosage strengths and administration schedules.
• Methods for treating schizophrenia and related psychiatric conditions.
• Manufacturing processes for producing the injectable suspension.

Formulation claims can create a more significant barrier than a basic compound patent where a generic manufacturer must reproduce the same delivery profile. A generic applicant may attempt to design around particular excipients, particle-size limitations, concentration ranges, or administration protocols, but the regulatory product must still satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.

What was Luye’s Paragraph IV challenge?

Luye’s ANDA challenge placed the Aristada patent estate directly at issue under the Hatch-Waxman framework. Luye’s Paragraph IV position would have required it to establish, depending on the patent and asserted claims, that:

1. The proposed generic product did not infringe the relevant claims.
2. The claims were invalid for anticipation, obviousness, lack of written description, lack of enablement, or another statutory defect.
3. The claims were unenforceable, if Luye asserted an inequitable-conduct or related defense.

Alkermes, in turn, sought an order preventing FDA approval of Luye’s product until expiration of the patents at issue. The case did not reach a public merits decision, so the record does not establish whether Luye’s proposed product would have infringed or whether Alkermes’ claims would have survived invalidity challenges.

How did the Alkermes v. Luye case end?

The case ended through a negotiated resolution and dismissal. The publicly available docket reflects no reported trial verdict, claim-construction ruling resolving the dispute, or final judgment determining patent validity and infringement.

The principal consequences were:

Issue	Public result
Patent validity	Not adjudicated in a final merits decision
Patent infringement	Not adjudicated in a final merits decision
Injunction	No reported merits-based injunction
Settlement terms	Not publicly disclosed
Authorized generic	No publicly disclosed arrangement identified in the litigation record
Luye launch date	Not established by a public merits judgment
Orange Book patents	Not removed solely because of the settlement
Regulatory outcome	Dependent on the settlement, patent status, and FDA approval process

A Hatch-Waxman settlement can establish a negotiated generic entry date without invalidating the patents. It can also include restrictions on launch, licensing provisions, supply arrangements, or other commercial terms. Unless the agreement is filed publicly or reported to the Federal Trade Commission and Department of Justice in a form that discloses the relevant provisions, the precise business terms may remain confidential.

What is the Orange Book status of Aristada?

Aristada’s regulatory exclusivity must be separated from its patent protection.

Protection type	Effect
New drug exclusivity	Restricts certain FDA approvals for a statutory period
Orange Book patent listing	Gives the NDA holder a mechanism to receive Paragraph IV notice and sue
Patent term	May extend beyond regulatory exclusivity
Hatch-Waxman stay	Can delay FDA approval after timely patent litigation
Settlement entry date	May permit generic launch before patent expiration if agreed by the parties

FDA Orange Book listings are product-specific and can change as patents issue, expire, are delisted, or are added through continuation applications. The existence of a listed patent does not itself disclose the private settlement date negotiated between Alkermes and Luye.

Aristada also received FDA approval for multiple dosage strengths and dosing intervals. Patent protection can vary by claim set and may not apply identically to every strength or administration schedule.

When does Aristada lose exclusivity?

Aristada’s practical loss of exclusivity depends on four separate dates:

1. Expiration of applicable Orange Book patents.
2. Expiration of any pediatric or other patent-term extensions.
3. The negotiated generic entry date in the Luye settlement.
4. FDA approval of Luye or another ANDA applicant.

The foundational Aristada patent estate has different expiration dates because the patents belong to separate families and have different priority dates. Later continuation patents can create additional barriers, although their claims may cover narrower formulation or manufacturing features.

The Luye settlement does not by itself establish that all Aristada patents expire on a single date. It also does not establish that Luye received a license to every Alkermes patent family. A commercial entry date must be confirmed from the settlement, subsequent FDA approval records, or a later public filing.

What patent litigation affects Aristada besides the Luye case?

Aristada has been the subject of broader generic-entry activity involving other ANDA applicants. The relevant competitive litigation landscape includes disputes concerning:

• Aripiprazole lauroxil composition claims.
• Extended-release injectable suspension claims.
• Dosage and administration claims.
• Pharmaceutical formulation and particle characteristics.
• Manufacturing and process claims.
• Patent-term and Orange Book listing issues.

The existence of related cases against other generic manufacturers can materially affect the interpretation of the Luye settlement. A later defendant may challenge a different patent family, use a different formulation, or rely on a different noninfringement theory. One defendant’s settlement therefore does not automatically resolve the entire Aristada patent estate.

How strong was Alkermes’ patent estate against Luye?

Alkermes’ position was commercially meaningful but legally untested in this case.

Strengths

• The estate covered more than the aripiprazole molecule.
• Aristada uses a differentiated prodrug and long-acting delivery system.
• Injectable extended-release formulations can be difficult to design around while meeting FDA equivalence requirements.
• Orange Book listing enabled Alkermes to invoke the Hatch-Waxman litigation process.
• Multiple patent families potentially extended protection beyond the earliest foundational rights.

Risks

• Pharmaceutical formulation claims can face obviousness challenges based on known long-acting antipsychotic technologies.
• Narrow particle, concentration, excipient, or release-profile limitations may permit noninfringing alternatives.
• A Paragraph IV defendant can attack written description and enablement where the claims extend across broad formulation classes.
• Patent expiration dates differ by family, reducing the value of any single patent.
• A settlement eliminates the opportunity to obtain a favorable validity or infringement judgment.

The lack of a final merits decision means the Luye docket should not be treated as precedent confirming the strength of the Alkermes claims.

Did Luye receive a license or an agreed generic launch date?

The public case disposition confirms settlement and dismissal, but the principal commercial terms were not publicly disclosed in the docket materials identified for the action.

The settlement may have addressed:

• A license to market Luye’s ANDA product.
• A fixed entry date before expiration of one or more patents.
• Restrictions tied to FDA approval.
• A supply or manufacturing arrangement.
• A covenant not to sue.
• Treatment of later-issued continuation patents.
• A launch date contingent on patent, regulatory, or commercial events.

No public evidence from the dismissal alone establishes that Luye was authorized to launch immediately, that Alkermes agreed to an authorized generic, or that all Aristada patents were licensed.

What generic entry risks exist for Aristada?

The principal risk is product-specific rather than uniform across the entire market.

Risk	Assessment
Single generic launch	High commercial impact because Aristada is a branded specialty injectable
Multiple ANDA approvals	Greater price and market-share pressure
Formulation design-around	Possible where claims are narrow
Manufacturing challenge	Significant because sterile injectable production requires specialized facilities and controls
Patent continuation risk	Relevant if later patents cover unexpired formulation or process claims
Regulatory delay	Possible if FDA requires additional data for a complex injectable
Settlement-controlled entry	Entry may occur before the latest patent expiration under agreed terms

A generic aripiprazole lauroxil product would face more than ordinary oral-solid-dose substitution risks. The manufacturer must establish the required quality, sterility, manufacturing consistency, release characteristics, and bioequivalence profile. Those requirements can slow entry even after patent barriers are resolved.

How does Aristada compare with Abilify Maintena?

Aristada and Abilify Maintena compete in the long-acting injectable antipsychotic market but rely on different active pharmaceutical technologies.

Attribute	Aristada	Abilify Maintena
Active ingredient	Aripiprazole lauroxil	Aripiprazole monohydrate
Sponsor	Alkermes	Otsuka
Delivery	Extended-release intramuscular injection	Long-acting intramuscular injection
Patent strategy	Prodrug, formulation, release, administration, manufacturing	Drug product, formulation, dosing, and related technology
Generic risk	Complex injectable and prodrug barriers	Separate patent estate and regulatory pathway
Competitive issue	Longer dosing intervals and product differentiation	Established aripiprazole long-acting injectable franchise

The Luye litigation affected Aristada, not the Abilify Maintena patent estate. A generic entrant for one product would not automatically obtain approval for the other.

What is the commercial significance of the case?

The case protected Alkermes’ control over potential generic entry into a specialized long-acting injectable market. Aristada sales are exposed to generic competition once an ANDA applicant obtains approval and can legally launch.

Revenue exposure depends on:

• The settlement entry date.
• The number of approved generic competitors.
• Whether the generic is therapeutically substitutable under state pharmacy rules.
• Payer substitution policies.
• Clinical preference for long-acting injectable treatment.
• Manufacturing capacity for sterile injectable products.
• The scope and expiration of remaining Aristada patents.

A single generic launch typically creates less immediate erosion than several competing products, but injectable products can have high switching barriers because prescribers and treatment centers may be cautious about adopting a new manufacturer. Those barriers do not eliminate price pressure after substitution becomes available.

Key Takeaways

• Alkermes sued Luye in Delaware in 2019 over a Paragraph IV ANDA for generic aripiprazole lauroxil, the active ingredient in Aristada.
• The asserted technology concerned Aristada’s long-acting injectable prodrug and formulation system.
• The case ended by settlement and dismissal, without a public ruling on patent validity or infringement.
• Settlement terms, including any generic launch date or license, were not publicly disclosed in the case disposition.
• Aristada’s exclusivity depends on multiple patent families, FDA regulatory status, and any negotiated entry rights.
• The litigation did not resolve the full Aristada patent estate or determine the outcome of challenges by other generic applicants.
• Sterile injectable manufacturing and formulation requirements remain practical barriers even after patent restrictions expire.

FAQs About Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd.

Was Alkermes v. Luye a Hatch-Waxman case?

Yes. Alkermes filed the action under the Hatch-Waxman framework after Luye submitted an ANDA with Paragraph IV certifications concerning Aristada-related patents.

What generic drug did Luye seek to market?

Luye sought approval for a generic version of Aristada, an extended-release intramuscular aripiprazole lauroxil injection.

Did the court rule that Luye infringed Alkermes’ patents?

No public final merits ruling established infringement. The case ended through settlement and dismissal.

Did the settlement make Luye the first generic competitor?

The public dismissal does not establish whether Luye received first-to-file status, a specific launch date, or an authorized-generic arrangement.

Can another generic manufacturer still challenge Aristada patents?

Yes. A separate ANDA applicant can challenge different listed patents or assert different invalidity and noninfringement theories. The Luye settlement does not eliminate all possible Aristada patent litigation.

References

1. Alkermes Pharma Ireland Limited v. Luye Pharma Group Ltd., No. 1:19-cv-01340, U.S. District Court for the District of Delaware, docket filings and dismissal order.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations [Orange Book]. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2015). Aristada (aripiprazole lauroxil) prescribing information.

4. U.S. Patent No. 8,337,888. United States Patent and Trademark Office.

5. U.S. Patent No. 9,193,987. United States Patent and Trademark Office.

6. U.S. Patent No. 9,925,241. United States Patent and Trademark Office.

7. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e).